Inhibitory Effects of Calcitriol on the Growth of MCF-7 Breast Cancer Xenografts in Nude Mice: Selective Modulation of Aromatase Expression in vivo | springermedizin.de

Springer Medizin

nach oben

Discover Oncology

Erschienen in:

01.06.2011

Inhibitory Effects of Calcitriol on the Growth of MCF-7 Breast Cancer Xenografts in Nude Mice: Selective Modulation of Aromatase Expression in vivo

verfasst von: Srilatha Swami, Aruna V. Krishnan, Jennifer Y. Wang, Kristin Jensen, Lihong Peng, Megan A. Albertelli, David Feldman

Erschienen in: Discover Oncology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Calcitriol (1,25-dihydroxyvitamin D₃), the hormonally active metabolite of vitamin D, exerts many anticancer effects in breast cancer (BCa) cells. We have previously shown using cell culture models that calcitriol acts as a selective aromatase modulator (SAM) and inhibits estrogen synthesis and signaling in BCa cells. We have now examined calcitriol effects in vivo on aromatase expression, estrogen signaling, and tumor growth when used alone and in combination with aromatase inhibitors (AIs). In immunocompromised mice bearing MCF-7 xenografts, increasing doses of calcitriol exhibited significant tumor inhibitory effects (~50% to 70% decrease in tumor volume). At the suboptimal doses tested, anastrozole and letrozole also caused significant tumor shrinkage when used individually. Although the combinations of calcitriol and the AIs caused a statistically significant increase in tumor inhibition in comparison to the single agents, the cooperative interaction between these agents appeared to be minimal at the doses tested. Calcitriol decreased aromatase expression in the xenograft tumors. Importantly, calcitriol also acted as a SAM in the mouse, decreasing aromatase expression in the mammary adipose tissue, while increasing it in bone marrow cells and not altering it in the ovaries and uteri. As a result, calcitriol significantly reduced estrogen levels in the xenograft tumors and surrounding breast adipose tissue. In addition, calcitriol inhibited estrogen signaling by decreasing tumor ERα levels. Changes in tumor gene expression revealed the suppressive effects of calcitriol on inflammatory and growth signaling pathways and demonstrated cooperative interactions between calcitriol and AIs to modulate gene expression. We hypothesize that cumulatively these calcitriol actions would contribute to a beneficial effect when calcitriol is combined with an AI in the treatment of BCa.

Anzeige

1.

Goss P, Wu M (2007) Application of aromatase inhibitors in endocrine responsive breast cancers. Breast 16(Suppl 2):S114–S119PubMedCrossRef

2.

Riemsma R, Forbes CA, Kessels A, Lykopoulos K, Amonkar MM, Rea DW, Kleijnen J (2010) Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat 123:9–24PubMedCrossRef

3.

Rugo HS (2008) The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol 19:16–27PubMedCrossRef

4.

Geisler J, Lonning PE (2005) Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res 11:2809–2821PubMedCrossRef

5.

Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD (2007) Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 41:346–352PubMedCrossRef

6.

Mincey BA, Duh MS, Thomas SK, Moyneur E, Marynchencko M, Boyce SP, Mallett D, Perez EA (2006) Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 7:127–132PubMedCrossRef

7.

Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C, Jones M (2002) Aromatase—a brief overview. Annu Rev Physiol 64:93–127PubMedCrossRef

8.

Gombart AF, Luong QT, Koeffler HP (2006) Vitamin D compounds: activity against microbes and cancer. Anticancer Res 26:2531–2542PubMed

9.

Krishnan AV, Feldman D (2010) Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer 17:R19–R38PubMedCrossRef

10.

Krishnan AV, Feldman D (2010) Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol

11.

Krishnan AV, Trump DL, Johnson CS, Feldman D (2010) The role of vitamin D in cancer prevention and treatment. Endocrinol Metab Clin North Am 39:401–418, table of contents

12.

Trump DL, Deeb KK, Johnson CS (2010) Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J 16:1–9PubMedCrossRef

13.

Welsh J (2007) Targets of vitamin D receptor signaling in the mammary gland. J Bone Miner Res 22(Suppl 2):V86–V90PubMedCrossRef

14.

Krishnan AV, Swami S, Peng L, Wang J, Moreno J, Feldman D (2010) Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 151:32–42PubMedCrossRef

15.

Simboli-Campbell M, Narvaez CJ, van Weelden K, Tenniswood M, Welsh J (1997) Comparative effects of 1,25(OH)₂D₃ and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 42:31–41PubMedCrossRef

16.

Stoica A, Saceda M, Fakhro A, Solomon HB, Fenster BD, Martin MB (1999) Regulation of estrogen receptor-alpha gene expression by 1,25-dihydroxyvitamin D in MCF-7 cells. J Cell Biochem 75:640–651PubMedCrossRef

17.

Swami S, Krishnan AV, Feldman D (2000) 1alpha,25-Dihydroxyvitamin D₃ down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res 6:3371–3379PubMed

18.

Krishnan AV, Swami S, Feldman D (2010) Vitamin D and breast cancer: inhibition of estrogen synthesis and signaling. J Steroid Biochem Mol Biol 121:343–348PubMedCrossRef

19.

Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL (1997) Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 3:402–408PubMedCrossRef

20.

Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS (1999) 1,25-Dihydroxycholecalciferol (1,25-D₃) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res 59:2644–2649PubMed

21.

Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL (2001) Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 7:1043–1051PubMed

22.

Koshizuka K, Koike M, Asou H, Cho SK, Stephen T, Rude RK, Binderup L, Uskokovic M, Koeffler HP (1999) Combined effect of vitamin D₃ analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res Treat 53:113–120PubMedCrossRef

23.

Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D (2005) Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 65:7917–7925PubMedCrossRef

24.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25:402–408PubMedCrossRef

25.

Diaz-Cruz ES, Shapiro CL, Brueggemeier RW (2005) Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 90:2563–2570PubMedCrossRef

26.

Zhao H, Innes J, Brooks DC, Reierstad S, Yilmaz MB, Lin Z, Bulun SE (2009) A novel promoter controls Cyp19a1 gene expression in mouse adipose tissue. Reprod Biol Endocrinol 7:37PubMedCrossRef

27.

Zhao XY, Ly LH, Peehl DM, Feldman D (1999) Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D₃ and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 140:1205–1212PubMedCrossRef

28.

Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72:248–254PubMedCrossRef

29.

Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff AC (2009) NCCN Task Force Report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw 7(Suppl 6):S1–S21, quiz S22–S23PubMed

30.

Colston KW, Mackay AG, James SY, Binderup L, Chander S, Coombes RC (1992) EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 44:2273–2280PubMedCrossRef

31.

Flanagan L, Packman K, Juba B, O’Neill S, Tenniswood M, Welsh J (2003) Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J Steroid Biochem Mol Biol 84:181–192PubMedCrossRef

32.

VanWeelden K, Flanagan L, Binderup L, Tenniswood M, Welsh J (1998) Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D₃ analog, EB1089. Endocrinology 139:2102–2110PubMedCrossRef

33.

Zinser GM, Tribble E, Valrance M, Urben CM, Knutson JC, Mazess RB, Strugnell SA, Welsh J (2005) 1,24(S)-dihydroxyvitamin D₂, an endogenous vitamin D₂ metabolite, inhibits growth of breast cancer cells and tumors. Anticancer Res 25:235–241PubMed

34.

Jordan VC, Gottardis MM, Robinson SP, Friedl A (1989) Immune-deficient animals to study “hormone-dependent” breast and endometrial cancer. J Steroid Biochem 34:169–176PubMedCrossRef

35.

Robinson SP, Jordan VC (1989) Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 49:1758–1762PubMed

36.

Santen RJ, Martel J, Hoagland M, Naftolin F, Roa L, Harada N, Hafer L, Zaino R, Pauley R, Santner S (1998) Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblasts. Breast Cancer Res Treat 49(Suppl 1):S93–99, discussion S109–S119PubMedCrossRef

37.

Purohit A, Tutill HJ, Day JM, Chander SK, Lawrence HR, Allan GM, Fischer DS, Vicker N, Newman SP, Potter BV, Reed MJ (2006) The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer. Mol Cell Endocrinol 248:199–203PubMedCrossRef

38.

Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S, Goloubeva O (2005) Therapeutic observations in MCF-7 aromatase xenografts. Clin Cancer Res 11:884s–888sPubMed

39.

Brodie A, Jelovac D, Sabnis G, Long B, Macedo L, Goloubeva O (2005) Model systems: mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem Mol Biol 95:41–48PubMedCrossRef

40.

Chow JD, Simpson ER, Boon WC (2009) Alternative 5′-untranslated first exons of the mouse Cyp19A1 (aromatase) gene. J Steroid Biochem Mol Biol 115:115–125PubMedCrossRef

41.

Somjen D, Kaye AM, Harell A, Weisman Y (1989) Modulation by vitamin D status of the responsiveness of rat bone to gonadal steroids. Endocrinology 125:1870–1876PubMedCrossRef

42.

Windahl SH, Lagerquist MK, Andersson N, Jochems C, Kallkopf A, Hakansson C, Inzunza J, Gustafsson JA, van der Saag PT, Carlsten H, Pettersson K, Ohlsson C (2007) Identification of target cells for the genomic effects of estrogens in bone. Endocrinology 148:5688–5695PubMedCrossRef

43.

Itoh S, Aubin JE (2009) A novel purification method for multipotential skeletal stem cells. J Cell Biochem 108:368–377PubMedCrossRef

44.

Syed FA, Modder UI, Roforth M, Hensen I, Fraser DG, Peterson JM, Oursler MJ, Khosla S (2010) Effects of chronic estrogen treatment on modulating age-related bone loss in female mice. J Bone Miner Res 25:2438–2446PubMedCrossRef

45.

Pino AM, Rodriguez JM, Rios S, Astudillo P, Leiva L, Seitz G, Fernandez M, Rodriguez JP (2006) Aromatase activity of human mesenchymal stem cells is stimulated by early differentiation, vitamin D and leptin. J Endocrinol 191:715–725PubMedCrossRef

46.

Celis JE, Moreira JM, Cabezon T, Gromov P, Friis E, Rank F, Gromova I (2005) Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial–adipocyte stromal cell interactions. Mol Cell Proteomics 4:492–522PubMedCrossRef

47.

Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA, Lee H, Temple K, Graves R, Pollard J, Chopra N, Russell RG, Sasisekharan R, Trock BJ, Lippman M, Calvert VS, Petricoin EF 3rd, Liotta L, Dadachova E, Pestell RG, Lisanti MP, Bonaldo P, Scherer PE (2005) Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest 115:1163–1176PubMed

48.

Bulun SE, Price TM, Aitken J, Mahendroo MS, Simpson ER (1993) A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 77:1622–1628PubMedCrossRef

49.

O’Neill JS, Elton RA, Miller WR (1988) Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br Med J (Clin Res Ed) 296:741–743CrossRef

50.

Agarwal VR, Bulun SE, Leitch M, Rohrich R, Simpson ER (1996) Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab 81:3843–3849PubMedCrossRef

51.

Harada N (1997) Aberrant expression of aromatase in breast cancer tissues. J Steroid Biochem Mol Biol 61:175–184PubMedCrossRef

52.

Zhou C, Zhou D, Esteban J, Murai J, Siiteri PK, Wilczynski S, Chen S (1996) Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. J Steroid Biochem Mol Biol 59:163–171PubMedCrossRef

53.

Meng L, Zhou J, Sasano H, Suzuki T, Zeitoun KM, Bulun SE (2001) Tumor necrosis factor alpha and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein alpha and peroxisome proliferator-activated receptor gamma: mechanism of desmoplastic reaction. Cancer Res 61:2250–2255PubMed

54.

Kinoshita Y, Chen S (2003) Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha. Cancer Res 63:3546–3555PubMed

55.

Laplante Y, Rancourt C, Poirier D (2009) Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors. Mol Cell Endocrinol 301:146–153PubMedCrossRef

56.

Shields-Botella J, Chetrite G, Meschi S, Pasqualini JR (2005) Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells. J Steroid Biochem Mol Biol 93:1–13PubMedCrossRef

57.

Brodie AM, Lu Q, Long BJ, Fulton A, Chen T, Macpherson N, DeJong PC, Blankenstein MA, Nortier JW, Slee PH, van de Ven J, van Gorp JM, Elbers JR, Schipper ME, Blijham GH, Thijssen JH (2001) Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol 79:41–47PubMedCrossRef

58.

Boyle BJ, Zhao XY, Cohen P, Feldman D (2001) Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165:1319–1324PubMedCrossRef

59.

Feldman D (1986) Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr Rev 7:409–420PubMedCrossRef

60.

Ly LH, Zhao XY, Holloway L, Feldman D (1999) Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D₃ to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 140:2071–2076PubMedCrossRef

61.

Muindi JR, Yu WD, Ma Y, Engler KL, Kong RX, Trump DL, Johnson CS (2010) CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology 151:4301–4312

62.

Peehl DM, Seto E, Hsu JY, Feldman DB (2002) Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J Urol 168:1583–1588PubMedCrossRef

Titel: Inhibitory Effects of Calcitriol on the Growth of MCF-7 Breast Cancer Xenografts in Nude Mice: Selective Modulation of Aromatase Expression in vivo
verfasst von: Srilatha Swami
Aruna V. Krishnan
Jennifer Y. Wang
Kristin Jensen
Lihong Peng
Megan A. Albertelli
David Feldman
Publikationsdatum: 01.06.2011
Verlag: Springer-Verlag
Erschienen in: Discover Oncology / Ausgabe 3/2011
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-011-0073-7

Anzeige

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.